Phenomix Files For IPO

San Diego-based Phenomix said in a filing with the SEC Friday that it is looking to raise up to $86.25M in an IPO on the NASDAQ Global Market. The firm, which is looking to list as "PHMX" on the exchange, develops biopharmaceuticals focused on treatment of Type 2 diabetes, along with compounds for treatment of hepatitis C infections. The IPO is being underwritten by Morgan Stanley, Credit Suisse, Oppenheimer & Co., and Pacific Growth Equities. Phenomix is venture backed by JP Morgan FUnds, Nomura Phase4 Ventures, Delphi Funds, Alta Partnres Funds, Sofinnova Funds, Novartis Funds, Baker Brothers Funds, Bay City Capital, and CMEA, among others.